标题
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
作者
关键词
-
出版物
Diabetes Therapy
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-09-30
DOI
10.1007/s13300-020-00930-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Sodium‐glucose linked transporter‐2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk
- (2020) Guntram Schernthaner et al. DIABETES OBESITY & METABOLISM
- Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
- (2020) David Z. I. Cherney et al. DIABETOLOGIA
- Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
- (2020) Björn Pasternak et al. BMJ-British Medical Journal
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
- (2019) Amar Ali et al. Diabetes Therapy
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis
- (2019) Kevin Bryan Lo et al. CardioRenal Medicine
- The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis
- (2019) Rosalie A. Scholtes et al. DIABETES OBESITY & METABOLISM
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
- (2018) Marie Ito et al. INTERNAL MEDICINE
- SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
- (2018) John Wilding et al. Diabetes Therapy
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study
- (2018) Joachim Gæde et al. DIABETOLOGIA
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- One-year eGFR decline rate is a good predictor of prognosis of renal failure in patients with type 2 diabetes
- (2017) Jun NOJIMA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health-related quality of life in different stages of chronic kidney disease
- (2016) H.K. Aggarwal et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
- Unmet need in diabetic nephropathy: failed drugs or trials?
- (2016) Dick de Zeeuw et al. Lancet Diabetes & Endocrinology
- Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2025
- (2015) Alexander Kainz et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
- (2015) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Markers of and Risk Factors for the Development and Progression of Diabetic Kidney Disease
- (2014) Richard J. MacIsaac et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007–2011
- (2014) Frank G. A. Assogba et al. DIABETOLOGIA
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
- (2013) M. Afkarian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension
- (2012) Peter Hansell et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs
- (2012) N. Hex et al. DIABETIC MEDICINE
- The proximal tubule in the pathophysiology of the diabetic kidney
- (2011) Volker Vallon AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- GFR Decline and Mortality Risk among Patients with Chronic Kidney Disease
- (2011) R. M. Perkins et al. Clinical Journal of the American Society of Nephrology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started